MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

TG Therapeutics Inc

Fechado

SetorSaúde

35.75 -1.89

Visão Geral

Variação de preço das ações

24h

Atual

Mín

34.98

Máximo

36.61

Indicadores-chave

By Trading Economics

Rendimento

23M

28M

Vendas

20M

141M

P/E

Médio do Setor

96.737

37.257

Margem de lucro

19.97

Funcionários

370

EBITDA

25M

38M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+16.71% upside

Dividendos

By Dow Jones

Próximos Ganhos

3 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.3B

5.8B

Abertura anterior

37.64

Fecho anterior

35.75

Sentimento de Notícias

By Acuity

34%

66%

124 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

TG Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de out. de 2025, 20:45 UTC

Ganhos

Costco Wholesale Sales Climb in September, Early October

8 de out. de 2025, 20:12 UTC

Grandes Movimentos do Mercado
Aquisições, Fusões, Aquisições de Empresas

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 de out. de 2025, 16:39 UTC

Grandes Movimentos do Mercado

Mining Shares Rise as Gold Prices Soar

8 de out. de 2025, 23:45 UTC

Conversa de Mercado

Nikkei May Rise on Weaker Yen -- Market Talk

8 de out. de 2025, 23:43 UTC

Conversa de Mercado

Gold Falls on Possible Profit-Taking -- Market Talk

8 de out. de 2025, 23:18 UTC

Aquisições, Fusões, Aquisições de Empresas

JD Logistics to Finance Acquisition Using Internal Funds

8 de out. de 2025, 23:17 UTC

Aquisições, Fusões, Aquisições de Empresas

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 de out. de 2025, 23:16 UTC

Aquisições, Fusões, Aquisições de Empresas

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 de out. de 2025, 21:54 UTC

Conversa de Mercado
Ganhos

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 de out. de 2025, 21:30 UTC

Conversa de Mercado

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 de out. de 2025, 21:26 UTC

Conversa de Mercado
Ganhos

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

8 de out. de 2025, 19:15 UTC

Conversa de Mercado

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 de out. de 2025, 19:01 UTC

Conversa de Mercado

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 de out. de 2025, 18:47 UTC

Conversa de Mercado

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

TaskUs Will Remain a Publicly Traded Co >TASK

8 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 de out. de 2025, 18:45 UTC

Aquisições, Fusões, Aquisições de Empresas

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 de out. de 2025, 18:07 UTC

Conversa de Mercado

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 de out. de 2025, 16:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Energy & Utilities Roundup: Market Talk

8 de out. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

8 de out. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

8 de out. de 2025, 15:57 UTC

Conversa de Mercado

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 de out. de 2025, 15:56 UTC

Conversa de Mercado

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 de out. de 2025, 15:53 UTC

Conversa de Mercado

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 de out. de 2025, 15:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 de out. de 2025, 15:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 de out. de 2025, 15:43 UTC

Aquisições, Fusões, Aquisições de Empresas

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 de out. de 2025, 15:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Comparação entre Pares

Variação de preço

TG Therapeutics Inc Previsão

Preço-alvo

By TipRanks

16.71% parte superior

Previsão para 12 meses

Média 42.6 USD  16.71%

Máximo 60 USD

Mínimo 11 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para TG Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

5 ratings

3

Comprar

1

Manter

1

Vender

Pontuação Técnica

By Trading Central

N/A / 34.86Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

124 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat